The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12623000334606
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/03/2023
Date registered
Help: Date registered
31/03/2023
Date last updated
Help: Date last updated
25/10/2025
Date data sharing statement initially provided
Help: Data sharing statement date
31/03/2023
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Equitable access to full blood examination testing at the point of care in remote primary health
Scientific title
Sepsis Point-of-Care Testing Trial (SPOCTrial), a pragmatic stepped wedge cluster-randomised trial, with embedded economic and process evaluations, of a new model of care for sepsis in remote primary health care that incorporates a full blood examination test at the point of care
Additional trial identifiers [1] 309136 0
2016006
Universal Trial Number (UTN)
Trial acronym
SPOCTrial
Related trial records

Health condition
Health condition(s) studied:
Sepsis 329235 0
Condition category
Condition code
Infection 326191 326191 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The SPOCTrial is a multi-component intervention that introduces a new model of care for sepsis detection. The nine intervention components are detailed below.
1. POC FBE Testing System, Connectivity and Consumables
The core component of the SPOCTrial intervention is the inclusion of a POC FBE test within the Primary Health Care Sepsis Pathway(s). To enable this test, the PixCell HemoScreen™ POC FBE device and associated equipment will be installed within a suitable location at each participating health centre during the transition month.
The POC FBE testing system, including connectivity and consumables consists of:
• 1x PixCell HemoScreen POC FBE device.
• 1x Citizen printer.
• 1x barcode scanner (optional).
• 1x Dell OptiPlex Micro.
• MediTrac and Atellica® Connect POC Insights software (Siemens Healthcare Pty Ltd).
• 1x 4G data SIM and dongle.
• CBC cartridges.
• CBC samplers.
• HemoCups.
The POC FBE testing system will be available for health care professionals to use with clients as needed throughout the transition and intervention phases.
2. Introductory Education and Site Assessment
Each participating health centre will receive an introductory education session covering the SPOCTrial protocol and intervention, the Primary Health Care Adult and Paediatric Sepsis Pathways, the CARPA Standard Treatment Manual’s early recognition of sepsis acute assessment protocol, how POC FBE tests fit within these, and a demonstration of POC FBE testing system. The session (~1 hr) will be delivered by the SPOCTrial PixCell Operations and Clinical Support Team member(s) to Site Principal Investigator (PI), Primary Health Centre Managers (PHCM) and other relevant health centre and health organisation staff (to be determined locally). Each health centre will receive at least one session during the transition period, or within 4 weeks prior and can be repeated as many times as requested by the PHCM, Site PI or local PixCell Champion during the transition and intervention phases. This session will be interactive and allow participants to ask questions to ensure they have a good understanding of the SPOCTrial intervention and to identify any local issues which may impact implementation. Frequently asked questions will be noted and used to improve future education sessions.
During the transition period, a site assessment will be conducted by SPOCTrial PixCell Operations and Clinical Support Team member(s) with the PHCM, local PixCell Champion, Site PI or delegate(s). The site assessment will cover local context, identify the PixCell Champion(s), appropriate physical locations for POC FBE test system and consumables, consumable delivery options, and local barriers to the SPOCTrial.
3. Sepsis and Primary Health Care Sepsis Pathways and Guidelines
To ensure all participating health care professionals understand how to identify sepsis, have knowledge of sepsis management and familiarity with the Primary Health Care Sepsis Pathway(s), and CARPA Standard Treatment Manual, they will be required to complete the self-guided ‘Early Sepsis Recognition and Management’ eLearning course administered through the NT Remote Locum Program, or equivalent.
4. POC FBE Testing Resource Package
During the transition period, each health centre will receive a folder containing hardcopies of resource to support POC FBE testing. Softcopy resources will be made available on the SPOCTrial website. The resource package includes:
• SPOCTrial Handbook (guidelines and requirements of POC FBE testing, training and competency certification and quality management).
• Quick reference posters (laminated set also available in A3 or A4 sizes).
• Quality management forms.
• Troubleshooting guides.
• Normal reference intervals for client tests.
• Client and quality result interpretation guides.
The resources will be updated as necessary by the SPOCTrial PixCell Operations and Clinical Support Team during the intervention phase, and additional site-specific resources can be developed if requested by health centres.
A form for the manual recording of client POC FBE test results in electronic health records (eHR) will be provided by the SPOCTrial PixCell Operations and Clinical Support Team to the administering organisation of each participating health centre. The template contains mandatory required data fields, but additional fields can be added to meet the local needs of each organisation.
5.PixCell POC FBE Testing Operator Training and Competency Assessment
Each health professional will need to complete mandatory training and achieve competency certification at least every 12-months. Upon certification of operator competency, each health care professional will receive a unique operator ID providing them access to the PixCell HemoScreen device and POC FBE testing. Training will be available via a self-guided eLearning course, or via an equivalent trainer-guided videoconference or face-to-face session. Competency assessment will include knowledge assessments (available via eLearning course or hardcopy) and a skills check involving quality control tests, which can be self- or trainer-guided (videoconference or face-to-face). Health care professionals can complete training as individuals or in small groups during the transition period, or at any time during the intervention phase.
Initial operator training and competency assessment will take approximately 1.5 hours to complete and subsequent re-certifications approximately 1 hour. The eLearning course and competency assessments will cover:
• How the FBE test fits within the sepsis pathways.
• Technical specifications of the HemoScreen™ POC FBE testing device, associated consumables and accessories
• Sample collection requirements.
• Client testing process.
• How to accurately record test results.
• Result interpretation.
• Quality management materials, activities and procedures (quality control [QC] and external quality assurance [EQA] testing, maintenance).
• Biosafety considerations.
• Common sources of error and risk mitigation strategies.
• Troubleshooting.
• Available support and clinical governance systems and resources.
• Operator roles and responsibilities.
• Clinical uses of POC FBE test outside of sepsis.
6. Quality Management Framework
A quality management framework is essential to monitoring and managing the quality of POC FBE testing and ensuring client safety. The following materials and resources will be provided by the by the SPOCTrial PixCell Operations and Clinical Support Team in the transition period and throughout the intervention phase:
• QC kits.
• EQA program.
• Device maintenance requirements.
• Annual quality testing schedule.
• Forms for recording quality management activities (can be tailored to each site).
• QC targets and limits.
• QC troubleshooting guides.
• Site-specific forms and resources (as requested).
• Clinical and Quality Advisory Group.
The SPOCTrial PixCell Operations and Clinical Support Team and the Clinical and Quality Advisory Group will oversee quality management with the following tasks:
• Record and monitor quality testing, device maintenance, operator competency, errors and flagged results using Atellica® Connect POC Insights software.
• Coordinate supply of QC kits and EQA materials to health centres throughout the transition and intervention phases.
• Supply quality testing schedule, forms and resources to health centres throughout the transition and intervention phases.
• Regularly communicate with health centres and PixCell Champions to manage mandatory completion of QC and EQA testing according to schedule (monthly QC tests, four EQA testing events per annum) throughout the intervention phase.
• Regularly communicate with Clinical and Quality Advisory Group to manage quality and safety issues.
The Clinical and Quality Advisory Group will provide clinical oversight of POC FBE testing as per the NPAAC Requirements for Point of Care Testing (2nd Edition 2021).
7. SPOCTrial PixCell Operations and Clinical Support Team (external facilitators)
Due to remoteness and the transient workforce in the remote primary health care setting, facilitation of POC testing is most efficiently achieved by external facilitators.
8. Ongoing Education and Engagement
To promote acceptability, adoption, effectiveness, reach and sustainability of the SPOCTrial intervention, several optional materials will be offered in a range of formats to facilitate ongoing education and engagement throughout the intervention phase. These optional materials will be developed by the SPOCTrial PixCell Operations and Clinical Support Team and delivered to certified PixCell operators, relevant medical officers and other relevant health centre/organisation staff.
9. PixCell Champion (internal facilitator)
A local health care professional with current PixCell operator certification will be nominated by each health centre to fulfil the role of PixCell Champion. PixCell Champions will:
• Assist with local orientation of relevant staff to the POC FBE testing system.
• Liaise with SPOCTrial PixCell Operations and Clinical Support Team to coordinate local POC FBE quality management activities including QC and EQA testing and device maintenance activities (i.e. software updates, cleaning, consumable orders and deliveries).
• Liaise with SPOCTrial PixCell Operations and Clinical Support Team to resolve local issues with PixCell device, quality management, operator training.
• Advocate for the SPOCTrial at the health centre.
Intervention code [1] 325718 0
Treatment: Devices
Description of the comparator or control
Participating remote primary health care centres will continue with their usual model of care for screening clients with suspected sepsis, which may include delayed FBE test results provided by a pathology laboratory or no FBE test (when obtaining delayed laboratory FBE results is impractical).
Primary health care centres that have already adopted the NT’s Primary Care Sepsis Pathways will utilise these during the control period, but without access to the POC FBC or white blood count (WBC) test. Other centres will not have adopted these pathways yet, so will use the the CARPA ‘Early Recognition of Sepsis’ Acute Assessment (Gateway) Protocol (8th Edition).
Control group
Active

Outcomes
Primary outcome [1] 334067 0
Time (in minutes) from a client’s initial presentation at a participating remote primary health care centre to time of intravenous antibiotic administration for sepsis or suspected sepsis as collected from medical records.
Timepoint [1] 334067 0
From time of presentation to time of treatment with antibiotics within 6 months of intervention implementation at the site.
Secondary outcome [1] 419262 0
Incidence of septic shock as assessed from medical records.
Timepoint [1] 419262 0
At 6 months after the intervention implementation at the site.
Secondary outcome [2] 419263 0
Number of medical evacuations for suspected sepsis as assessed from medical records.
Timepoint [2] 419263 0
At 6 months after the intervention implementation at the site.
Secondary outcome [3] 420272 0
Calculating the different between resource use and costs from primary care and hospital medical records and cost-benefit of the new model of care from outcome data. Annualised costs of the POC FBE device and other resources associated with implementation will be estimated from data collected alongside the study implementation of the POC FBE device. The cost of lab-based FBE testing and health care for sepsis will be calculated, including test ordering and care provided by participating clinics, evacuations and hospital admissions (reports on evacuations and hospital admissions are recorded in patient information system). Required cost parameters will be sourced in collaboration with partner organisation NT Health. The cost model will estimate the expected difference in costs associated with the care of sepsis between an intervention and a usual care patient, to which the estimated POC FBE implementation cost per sepsis patient will be added.
Timepoint [3] 420272 0
At 6 months after the intervention implementation at the site.

Eligibility
Key inclusion criteria
Patients diagnosed with sepsis after presenting at a participating health centre.
Minimum age
2 Months
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Any patient that initially presents to a primary health care centre that does not have a FBE POC testing device and is referred to a nearby primary health care centre that does have a FBE POC testing device.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stepped wedge cluster randomised trial of 21 participating sites randomised into 4 clusters of 5 sites per cluster (6 sites in last cluster to mitigate the risk of site attrition in earlier clusters) via a computer-generated list of random numbers.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Non-concealed allocation of 21 participating sites.
Randomised into 4 clusters of 5 sites per cluster (6 sites in last cluster to mitigate the risk of site attrition in earlier clusters) via a computer-generated list of random numbers.
Sequential crossover of clusters from control to intervention until all clusters are exposed.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
To estimate the expected power of the trial to detect statistically significant improvements in the primary outcome (time to treatment initiation) the expected number of sepsis cases in the trial was estimated using data reported by a prospective cohort study that reported an aggregate rate of 11.8 hospital admissions for community acquired sepsis per 1,000 population per year across the Top End of the NT and a rate of 40.8 for Indigenous people (who comprised 27% of the catchment population).[1] The average community size served by remote primary healthcare centres is 900 (70% Indigenous peoples).[2] From these data, over 1,100 cases of community acquired sepsis leading to hospitalisations are expected across the study clinics over the 2.5-year time horizon of the trial. This is a conservative figure as not all cases of sepsis will be hospitalised. The power calculation is based on the primary outcome of time to treatment with antibiotics. A pilot extraction of data for 30 patients from the PCIS demonstrated a mean of 140 minutes’ time gap with standard deviation of 129 minutes between initial presentation to IV antibiotics in the standard care. A sample of 20 clusters in a complete stepped-wedge cluster-randomized design with 4 steps, with 5 cluster(s) switching from control to treatment at each step, with an average of 11 participants per cluster per time period (for a total sample size of 1,100 participants) achieves 90% power to detect a difference between means of 41 minutes (e.g., an average of 140 minutes in control group and 99 minutes in intervention group). The test statistic used is the two-sided Wald Z-Test. The assumed intra cluster correlation (ICC) is 0.050, and the significance level of the test is set to 0.05. One additional site, giving 21 participating sites in total, has been added to mitigate the risk of site attrition in earlier clusters.

1. Davis JS, Cheng AC, McMillan M, et al. Sepsis in the tropical Top End of Australia’s Northern Territory: disease burden and impact on Indigenous Australians. Med J Aust. 2011;194:519-24.

2. Australian Bureau of Statistics (2016) Estimates of Aboriginal and Torres Strait Islander Australians [ww.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-aboriginal-and-torres-strait-islander-australians/latest-release], accessed 11 February 2022.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NT

Funding & Sponsors
Funding source category [1] 313339 0
Government body
Name [1] 313339 0
NHMRC 2021 Medical Research Future Fund Primary Health Care Research
Country [1] 313339 0
Australia
Primary sponsor type
University
Name
Flinders University
Address
Sturt Rd, Bedford Park SA 5042
Country
Australia
Secondary sponsor category [1] 315083 0
None
Name [1] 315083 0
Not applicable.
Address [1] 315083 0
Not applicable.
Country [1] 315083 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 312561 0
Human Research Ethics Committee of NT Health and Menzies School of Health Research
Ethics committee address [1] 312561 0
Ethics committee country [1] 312561 0
Australia
Date submitted for ethics approval [1] 312561 0
05/04/2023
Approval date [1] 312561 0
26/06/2023
Ethics approval number [1] 312561 0
2023-4597

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 125094 0
Dr Brooke Spaeth
Address 125094 0
Level 3, Health Sciences Building, Flinders University BEDFORD PARK SA 5041
Country 125094 0
Australia
Phone 125094 0
+61 0882017792
Fax 125094 0
Email 125094 0
Contact person for public queries
Name 125095 0
Brooke Spaeth
Address 125095 0
Level 3, Health Sciences Building, Flinders University BEDFORD PARK SA 5041
Country 125095 0
Australia
Phone 125095 0
+61 0882017792
Fax 125095 0
Email 125095 0
Contact person for scientific queries
Name 125096 0
Brooke Spaeth
Address 125096 0
Level 3, Health Sciences Building, Flinders University BEDFORD PARK SA 5041
Country 125096 0
Australia
Phone 125096 0
+61 0882017792
Fax 125096 0
Email 125096 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: This research involves participating primary health care services located in remote Northern Territory communities, which primarily service Aboriginal and Torres Strait Islander peoples, as such, due to cultural, ethical, and sensitivity considerations, IPD will not be made publicly available.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.